Lyra Therapeutics Inc. (LYRA): Price and Financial Metrics

Lyra Therapeutics Inc. (LYRA)

Today's Latest Price: $13.88 USD

2.75 (24.71%)

Updated Nov 24 4:00pm

Add LYRA to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

LYRA Stock Price Chart Interactive Chart >

Price chart for LYRA

LYRA Price/Volume Stats

Current price $13.88 52-week high $22.00
Prev. close $11.13 52-week low $10.37
Day low $12.55 Volume 972,400
Day high $15.36 Avg. volume 88,019
50-day MA $11.53 Dividend yield N/A
200-day MA $0.00 Market Cap 179.43M

Lyra Therapeutics Inc. (LYRA) Company Bio

Lyra Therapeutics, Inc. is a clinical-stage therapeutics company. It develops novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat, or ENT, diseases. The firms proprietary XTreo deliver medicines. The company was founded by Carmichael S. Roberts, George M. Whitesides, and Robert S. Langer and is headquartered in Watertown, MA.

LYRA Latest News Stream

Event/Time News Detail
Loading, please wait...

LYRA Latest Social Stream

Loading social stream, please wait...

View Full LYRA Social Stream

Latest LYRA News From Around the Web

Below are the latest news stories about Lyra Therapeutics Inc that investors may wish to consider to help them evaluate LYRA as an investment opportunity.

Lyra Therapeutics presents positive LYR-210 data in rhinosinusitis

Lyra Therapeutics ([[LYRA]] +0.9%) presents data showing that LYR-210 demonstrated a significant reduction of sinonasal Type 2 inflammation in surgically naïve patients with chronic rhinosinusitis ((CRS)) (inflammation of the sinuses and nasal cavity).As previously announced, results from Phase 1 study demonstrated LYR-210 significant improvement in sinonasal outcome (SNOT-22), with (p<0.05) reduced sinonasal...

Seeking Alpha | September 11, 2020

Lyra Therapeutics, Inc. (LYRA) CEO Maria Palasis on Q2 2020 Results - Earnings Call Transcript

Lyra Therapeutics, Inc. (LYRA) Q2 2020 Earnings Conference Call August 5, 2020 04:30 PM ET Company Participants Laurence Watts - Managing Director Gilmartin Group Maria Palasis - President and Chief Executive Officer Don Elsey - Chief Financial Officer Corinne Noyes - Senior Vice President of Commercial Strategy and Market Development...

SA Transcripts on Seeking Alpha | August 11, 2020

Read More 'LYRA' Stories Here

LYRA Price Returns

1-mo 14.43%
3-mo 4.05%
6-mo -12.54%
1-year N/A
3-year N/A
5-year N/A
2019 N/A
2018 N/A
2017 N/A
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.9011 seconds.